CAS: 1189767-28-9; 6-(Pyridin-2-Ylmethyl)-1-(Tetrahydro-2H-Pyran-4-yl)-1,7-Dihydro-4H-Pyrazolo[3,4-D]Pyrimidin-4-One
- 英文名称6-(Pyridin-2-Ylmethyl)-1-(Tetrahydro-2H-Pyran-4-yl)-1,7-Dihydro-4H-Pyrazolo[3,4-D]Pyrimidin-4-One
- 中文名称6-(吡啶-2-基甲基)-1-(四氢-2H-吡喃-4-基)-1,7-二氢-4H-吡唑并[3,4-D]嘧啶-4-酮
- IUPAC名称Osoresnontrine
- 其它别名6-(Pyridin-2-Ylmethyl)-1-(Tetrahydro-2H-Pyran-4-yl)-1,5-Dihydro-4H-Pyrazolo[3,4-D]Pyrimidin-4-One; 4H-Pyrazolo[3,4-D]Pyrimidin-4-One, 1,5-Dihydro-6-(2-Pyridinylmethyl)-1-(Tetrahydro-2H-Pyran-4-yl)-; 6-(Pyridin-2-Ylmethyl)-1-(Tetrahydro-2H-Pyran-4-yl)-1,7-Dihydro-4H-Pyrazolo[3,4-D]Pyrimidin-4-One; Osoresnontrine
- CAS编号1189767-28-9
- MFCD编号:MFCD31746892
- EINECS号:810-297-6
- FDA UNII编号:O9OC34WOAY
- 分子式:C16H17N5O2分子量:311.35
- 产品CID: 250114
- 同类组份化合物CAS1189767-28-9
- 产品分类Inhibitors/Agonists → Metabolic Enzyme → PDE
物理性质
MSDS等安全信息
欧盟法规
ECHA物质C&L通报合成工艺路线路线简述
海关参考信息
- 2905121000-正丙醇
2905130000-正丁醇
2909110000-乙醚
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophr Bull. 2018 May 1. doi: 10.1093/schbul/sby049. [Epub ahead of print] doi: 10.1016/j.euroneuro.2018.01.003. Epub 2018 Mar 19. doi: 10.1007/s40120-017-0085-5. Epub 2017 Nov 24.
4: Boland K, Moschetti V, Dansirikul C, Pichereau S, Gheyle L, Runge F, Zimdahl-Gelling H, Sand M. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. Hum Psychopharmacol. 2017 Jan;32(1). doi: 10.1002/hup.2569. doi: 10.1111/bcp.13060. Epub 2016 Aug 22.
6: Mason VL. Alzheimer's Association International Conference on Alzheimer's Disease 2015 (AAIC 2015) (July 18-23, 2015 - Washington, D.C., USA). Drugs Today (Barc). 2015 Jul;51(7):447-52. doi: 10.1358/dot.2015.51.7.2375989.
合成参考文献
参考文献:10.1093/schbul/sby049
摘要:Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophr Bull. 2019 Mar 07;45(2):350–9.
📝 需求与反馈
尽可能描述清楚需求与问题信息
